跳至主要内容
临床试验/CTRI/2025/08/093211
CTRI/2025/08/093211尚未招募3 期

A CONTROLLED COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF TRIKATUKADI CHURNA OVER HINGWADI CHURNA IN THE MANAGEMENT OF UDAVARTINI YONIVYAPAD W.S.R TO PRIMARY DYSMENORRHEA

DR ARCHANA G N1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年8月30日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1
主要终点
Effect of trial drug on improvement in classical symptoms of Udavartini Yonivyapad (Primary Dysmenorrhea)

研究概览

简要总结

Primary dysmenorrhea is a common, disregarded, underdiagnosed and inadequately treated complaint which slows down the women in her day to day activity and has a major impact on women’s quality of life, work productivity and healthcare utilization.The prevalence of dysmenorrhea varies between 16% - 91% in women of reproductive age with severe pain in 2% - 29% of the women studied. Udavartini Yonivyapadcaused due to movement of Vata in upward direction (Udavartana) caused by Vatakopa due to Vegadharana or functional disturbance or secondary to obstruction of Vata further causing pain and displacement of rajas which is expelled with great difficulty.

In Modern system of medicine, non-addictive analgesics are prescribed in the primary dysmenorrhea which includes NSAID’S, Hormonal treatment and Anti-spasmodic drugs. In this scenario rather than hormonal treatment, Ayurvedic herbo-mineral treatment is proved to be effective in Udavartini Yonivyapad. Keeping this in mind to find a suitable remedy which will be gentle, non-hormonal safe and effective alternate in the management of Dysmenorrhea. The main Dosha causing Udavartini Yonivyapad is Vata. Trikatukadi Churna4 and Hingwadi Churna5 is having Anulomana, Vatakapha Hara and Shoola Prashamanaproperties. So here is an attempt to evaluate and compare the efficacy of trial drug Trikatukadi Churna and control drug of Hingwadi Churna in the management of Udavartini Yonivyapad w.s.r to Primary Dysmenorrhea.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
15.00 Year(s) 至 35.00 Year(s)(—)
性别
Female

入选标准

  • 1 Patients of age between 15-35 years.
  • 2 Patients complaining painful menstruation for atleast 2 consecutive cycle.
  • 3 Pratyatma Lakshana of Udavartini Yonivyapad.
  • 4 Patient willing to sign the consent form.

排除标准

  • 1 K/C/O–Fibroid Uterus, PID, Carcinoma of endometrium, Menorrhagia, Endometriosis, Adenomyosis.
  • 2 K/C/O – Systemic diseases like DM, HTN and Thyroid.
  • 3 K/C/O – Congenital anomaly.

结局指标

主要结局

Effect of trial drug on improvement in classical symptoms of Udavartini Yonivyapad (Primary Dysmenorrhea)

时间窗: 6th day of 1st menstrual cycle, | 6th day of 2nd menstrual cycle, | 6th day of 3rd menstrual cycle

次要结局

  • Safety of the trial drug and adverse drug reaction and aggravation in the symptoms of Udavartini yonivyapad(Primary Dysmenorrhea)(6th day of 1st menstrual cycle,)

研究者

发起方
DR ARCHANA G N
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

DR ARCHANA G N

Sidramappa Danigond Memorial Trusts Ayurvedic Medical College Post Graduation Centre

研究点 (1)

Loading locations...

相似试验